InflaRx N.V. Common Stock (IFRX) Stock Price

IFRXStock

$1.32+6.45%52W

Market Cap$194.53M

P/E—

PEG Ratio—

Div yield—

Beta2.45

IFRX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)5.88%

Price vs S&P 500 (4W)-36.41%

VGM Score27.39

Book Value / Share (Quarterly)$1.11

P/TBV (Annual)1.45x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.18

Price vs S&P 500 (YTD)18.77%

Gross Margin (TTM)-3693.72%

Net Profit Margin (TTM)-42170.98%

EPS (TTM)$-0.39

10-Day Avg Trading Volume0.73M

EPS Excl Extra (TTM)$-0.39

EPS (Annual)$-0.76

ROI (Annual)-107.39%

Gross Margin (Annual)-24678.79%

Cash / Share (Quarterly)$1.21

Revenue Growth QoQ (YoY)-80.75%

ROA (Last FY)-82.65%

Revenue Growth TTM (YoY)-85.40%

EBITD / Share (TTM)$-0.31

ROE (5Y Avg)-60.62%

Operating Margin (TTM)-35401.52%

Cash Flow / Share (Annual)$-0.55

P/B Ratio1.18x

P/B Ratio (Quarterly)2.01x

Net Income / Employee (Annual)$-788,114

EV / Revenue (TTM)2681.09x

Net Interest Coverage (TTM)-13.98x

ROA (TTM)-30.43%

EPS Incl Extra (Annual)$-0.76

Current Ratio (Annual)4.13x

Quick Ratio (Quarterly)8.10x

3-Month Avg Trading Volume0.92M

52-Week Price Return6.45%

Revenue / Employee (TTM)$449

Tangible BV / Share (Quarterly)$1.11

P/S Ratio (Annual)5901.44x

Asset Turnover (Annual)0.00x

52-Week High$3.31

EPS Excl Extra (Annual)$-0.76

CapEx CAGR (5Y)4.20%

Tangible BV CAGR (5Y)-11.74%

26-Week Price Return15.79%

Quick Ratio (Annual)3.88x

13-Week Price Return-28.84%

Total Debt / Equity (Annual)0.02x

Current Ratio (Quarterly)8.22x

Enterprise Value$190.38M

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-26.92%

Revenue / Employee (Annual)$561

Pretax Margin (Annual)-155545.52%

Cash / Share (Annual)$0.72

3-Month Return Std Dev64.97%

Net Income / Employee (TTM)$-492,220

ROE (Last FY)-109.81%

Net Interest Coverage (Annual)-5.86x

EPS Basic Excl Extra (Annual)$-0.76

Receivables Turnover (TTM)0.02x

Total Debt / Equity (Quarterly)0.01x

EPS Incl Extra (TTM)$-0.39

ROI (TTM)-36.99%

P/S Ratio (TTM)2736.16x

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.64

Price vs S&P 500 (52W)-9.08%

Year-to-Date Return30.69%

5-Day Price Return-16.98%

EPS Normalized (Annual)$-0.76

ROA (5Y Avg)-48.80%

Net Profit Margin (Annual)-155587.38%

Month-to-Date Return-26.67%

Cash Flow / Share (TTM)$-0.82

EBITD / Share (Annual)$-0.80

Operating Margin (Annual)-164539.45%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-59.62%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.39

P/TBV (Quarterly)2.01x

P/B Ratio (Annual)1.45x

Inventory Turnover (TTM)0.71x

Pretax Margin (TTM)-42151.56%

Book Value / Share (Annual)$0.65

Price vs S&P 500 (13W)-31.53%

Beta2.45x

Revenue / Share (TTM)$0.00

ROE (TTM)-37.43%

52-Week Low$0.90

vGradeD

gGradeF

mGradeC

vgmGradeD

IFRX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.06	-$0.10	-63.64%(-$0.03)
Q1 2026	May 6, 2026	-$0.17	-$0.09	+45.76%(+$0.08)
Q4 2025	Mar 19, 2026	-$0.16	-$0.17	-2.74%(-$0.00)
Q3 2025	Nov 10, 2025	-$0.14	-$0.20	-46.94%(-$0.07)
Q2 2025	Aug 7, 2025	-$0.23	-$0.24	-3.28%(-$0.01)

IFRX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.14

4.21

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
IFRXInflaRx N.V. Common Stock	D	F	C	2736.2x	-85.4%	-3693.7%	—	$1.32
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About InflaRx N.V. Common Stock

InflaRx NV is a clinical-stage biopharmaceutical company developing targeted therapies for autoimmune and inflammatory diseases. The company's lead candidate, vilobelimab, is a first-in-class monoclonal antibody designed to inhibit C5a, a key inflammatory mediator implicated in multiple disease pathways. Clinical data has demonstrated disease-modifying activity and a favorable safety profile. The company is advancing this platform with plans to address multiple therapeutic indications.

IFRX Next Earnings Report

Report dateNov 9, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate-$0.06

Revenue estimate$0

Also reporting on Nov 9, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

Companies in Related Industries

FATEFate Therapeutics, Inc.Biological Products
PLXProtalix BioTherapeutics, Inc. Common StockBiological Products
ALECAlector, Inc. Common StockBiological Products
NAGENiagen Bioscience, Inc. Common StockPharmaceutical Preparations
CGENCompugen LtdBiological Products
LTBRLightbridge Corp.Industrial Chemicals
IVVDInvivyd, Inc. Common StockBiological Products
STROSutro Biopharma, Inc.Biological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.2

Strong Buy

Consensus rating

52-Week Range

Low$0.90

High$3.31